Clinical Trial Update: Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tigecycline versus clindamycin or vancomycin for complicated skin and skin-structure infections in pediatric patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin and Soft Tissue Infections

Drugs mentioned

• Clindamycin
• Tigecycline (tigecycline)
• Vancomycin (vancomycin)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Skin Diseases, Infection | Phase 3 | Status: WITHDRAWN